[28,29] Although clinical trial data are lacking, ACCP guidelines indicate that fondaparinux is an alternative to direct thrombin inhibitors in patients with HIT. [28] Since heparin-based products ...
Hypersensitivity to the pentasaccharide fondaparinux in patients with delayed-type heparin allergy. Thromb Haemost 2005; 94: 895–6. MEDLINE 20. Hirsch K, Ludwig RJ, Lindhoff-Last E, Kaufmann R ...
[2] Results of a meta-analysis of trials involving patients undergoing orthopedic surgery revealed a significantly lower overall rate of VTE with fondaparinux versus enoxaparin (6.8% versus 13.7% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback